A novel long-term prediction model showed promise at estimating the risk for dying of prostate cancer, an analysis published ...

A new combination of drugs could help delay the advancement of a deadly form of prostate cancer in those with an advanced form of the disease, new research has found. The “striking” findings showed an ...

A new long-term prediction tool estimates the risk of dying from prostate cancer, offering a more accurate way to interpret ...

Men treated for nonmetastatic prostate cancer under current guidelines are up to 6 times less likely to die from their cancer than from other causes, according to data from a Swedish cancer registry.

Prostate cancer is the second-leading cause of cancer death in American men. About 1 in 8 men will be diagnosed with prostate ...

Risk of death and cause of death 30 years after diagnosis as a proportion of 100 men. Grey figures indicate the proportion of men alive after 30 years, blue figures the proportion of men who died of ...

New research in JNCCN—Journal of the National Comprehensive Cancer Network finds that for people diagnosed with nonmetastatic low-risk prostate cancer later in life, and treated according to NCCN ...

In this cohort study, a novel prognostic model was developed to estimate prostate cancer-specific mortality (PCSM) while ...

The European Randomized Study of Screening for Prostate Cancer (ERSPC) was initiated in 1993 to assess the effect of prostate-specific antigen (PSA) testing on prostate cancer mortality. Because ...

Cancer survival in the U.S. has climbed to 70%, reflecting major advances in treatment, early detection and personalized care, new data show.